Next-generation antibody therapy for cancer

The Rader Lab pursues both antibody target and drug discovery strategies toward more specific and more potent treatment options for cancer patients.

Our target discovery efforts are aimed at identifying new cell surface antigens suitable for monoclonal antibody (mAb) therapy of cancer. Our drug discovery efforts have the objective to develop and utilize antibody display, antibody engineering, and antibody conjugation methods for improving the potency of mAbs. A particular focus in the Rader lab is devoted to antibody technologies at the interface of biology and chemistry, including the generation of molecularly defined antibody-drug conjugates (ADCs) and antibody-siRNA conjugates (ARCs) as well as chemically programmed bispecific antibodies (biAbs) and chimeric antigen receptor T cells (CAR-Ts). Collectively, these efforts have unveiled several new candidate targets, created a panel of new mAbs, and led to a diverse assortment of new and refined antibody technologies with broad utility for cancer therapy. Several of our targets, tools, and technologies have been translated to preclinical and clinical investigations through numerous collaborations with industry, academia, and government.